key: cord-1032559-8yak41ao authors: Taha, Muhanad; Sharma, Aditi; Taha, Mazen; Samavati, Lobelia title: COVID-19 in immunocompromised organ transplant recipients : A Case Report and Review of the Literature date: 2020-07-30 journal: Transplant Proc DOI: 10.1016/j.transproceed.2020.07.014 sha: 7ab0551d307a5123a5bc01ed826f4424ad617b89 doc_id: 1032559 cord_uid: 8yak41ao Abstract Coronavirus disease 2019 (COVID-19) is an ongoing pandemic caused by a novel coronavirus called SARS-CoV-2. Our Understanding of this new disease continues to grow. The impact of the disease on immunocompromised transplant recipients is largely unknown. We present a case of a solid organ transplant recipient on immunosuppressive therapy who successfully recovered from COVID-19 infection. We also review ten similar cases found in the literature and describe the clinical coarse and management including immunosuppressive therapy. A pneumonia caused by a novel coronavirus designated as Severe Acute Respiratory Syndrome We discuss the clinical course and the management of the disease, including immunosuppressive therapy. We speculate a possible mechanism of the potential effect of immunosuppressant in the course of this disease. A 43-year-old female who received a kidney transplant 12 years ago because of sickle cell nephropathy presented with one day history of nonproductive cough, shortness of breath, subjective fever and generalized musculoskeletal pain. Besides sickle cell disease, she has history of recurrent deep venous thrombosis treated with apixaban, pulmonary hypertension on 2 Liter home oxygen and essential hypertension. She was on maintenance immunosuppressive therapy with tacrolimus 3 mg daily and prednisone 5 mg daily. On admission, the patient was saturating well on 2 Liter Nasal cannula without distress. Other vital signs were within normal limit. On physical examination, the patient was found to have bronchial lung sounds on the right side. The rest of the examination was unremarkable. Laboratory tests showed acute kidney injury (Cr 2.2 mg/dl with baseline 1.8 mg/dL), neutrophilia and lymphopenia (see Table 1 ). Chest radiography done and showed opacity in right lower lobe (Figure 1 ), a finding consistent with pneumonia. Rapid nucleic acid amplification tests for influenza A and B and respiratory syncytial virus through nasal swab were reported as negative. Treatment with ceftriaxone and azithromycin for community acquired pneumonia was initiated. Patient was started on intravenous opioids for vasoocclusive pain crisis of sickle cell disease. On day 2 through 4 of hospitalization, the patient musculoskeletal pain improved but continued to report a nonproductive cough. On hospital day 5, the patient developed intermittent fevers and her oxygen requirement increased to 5 L Nasal cannula (Table 1) . Other vitals remain largely stable. Antibiotics coverage broaden to vancomycin, cefepime and azithromycin. A subsequent Chest computer tomographic (CT) revealed multiple bilateral ground-glass opacities ( Figure 2 ). A concern for acute chest syndrome with sickle cell disease was raised and the patient received two units of packed red blood cells (PRBCs). Blood and sputum cultures were obtained and shown no growth. Given the radiographic finding, persistence fever, increase supplemental oxygen requirement and the recent concern of COVID-19 in other states in US, patient was tested for COVID-19 with nasal swab nucleic acid test and the result was positive. Patient was one of the first COVID-19 cases discovered in Detroit Metro area. Patient denied recent travel or any contact with sick people. Patient acute kidney injury on admission improved to baseline after 5 days (Table 1) . Her immunosuppressive therapy of Tacrolimus 3 mg daily and prednisone 5 mg daily were never stopped and resumed during hospitalization. Tacrolimus trough level was within normal limits during hospitalization (Table 1) . Patient was not treated with any specific novel therapy for COVD-19. Laboratory test reflected neutrophilia and lymphopenia during hospitalization (Table 1) . C-Reactive Protein (CRP) and Lactate Dehydrogenase (LDH) have not been tested. Patient remained hemodynamically stable during hospitalization. On hospital day 7, the patient clinical condition improved. Vancomycin and cefepime were discontinued on day 8. Patient's fever and cough resolved. The oxygen requirement improved back to baseline (2 Liter Nasal cannula). Patient discharged home after 10 days of hospitalization. After reviewing the literature and to the date of this report, ten cases of COVID-19 infection in immunocompromised transplant recipients have been reported in the literature including the current case (See Table 2 ). Patients range in age from 37 to 75 years old. All patients in the series, except our case, were male. Presentation is typical in most cases, with fever and cough being the most presented symptoms. Diagnosis of COVID-19 was accomplished via nasal swab nucleic acid test. Most patients in the series had a kidney transplant and were on Mycophenolate or tacrolimus or both for immunosuppressive therapy. Computer Tomography (CT) findings were similar in most cases and showed bilateral ground-glass opacities. During hospitalization, immunosuppressive therapy held in five cases while continued in three cases including our case. Two cases did not comment about immunosuppressive therapy. All patients, except two cases, received antiviral therapy. Other therapies like Methylprednisolone, hydroxychloroquine and Intravenous Immunoglobulin (IVIG) have been received by other cases. Six patients experienced resolution of symptoms, did not require mechanical ventilation and discharged from hospital. Two cases were still in hospital while their cases reported. One was stable on non-invasive ventilation and the other one, according to further communication with the author, was extubated successfully and was recovering in medical floor. Two cases deceased, one was a 75 year old male 3 who developed acute worsening of respiratory status and deceased before mechanical intubation while the other one was a 58 year old male 2 who had severe respiratory distress requiring intubation and extracorporeal membrane oxygenation (ECMO) but had developed multiorgan failure and deceased. In our review, the age of patients who recovered and discharged or still in hospital were relatively younger than the two patients who expired. It is well known that infections after transplantation may present in atypical fashion and might promote transplant rejection 8 , however, our cases presented with typical symptoms and none of the cases reported transplant rejection during hospitalization. Advanced age and comorbidities like hypertension, diabetes mellitus, chronic lung and kidney disease have been associated with higher severity and mortality in COVID-19 infection [12] [13] [14] . However, specific data regarding risks associated with immunocompromised conditions are limited and further studies needed. Generally, these patients are more susceptible to bacterial, fungal, viral, and parasitic infections and have poor outcome compared to immunocompetent subjects 8 . However, this is not always the case, our experience from other types of coronavirus like Severe Acute Respiratory Syndrome-Related Coronavirus (SARS) 10 Respiratory Syndrome (MERS) 11 showed that immunosuppressed status was not a risk factor for disease severity. One hypothesis that might explain this is that immunosuppression therapies mitigate the inflammatory reaction triggered by the virus. This reaction, also called cytokine storm or hyperinflammation, which may play a major rule in COVID-19 severity and mortality 15 . Although our review showed high mortality rate with 2 out of 10 patients died, our sample is small and not sufficient to predict mortality and severity of illness in immunocompromised transplant recipients and further large studies are needed . Data regarding resuming or holding immunosuppressive therapy in COVID-19 are limited. Immunosuppressant may diminish antiviral host immunity, so some clinicians tend to hold or decrease the dose of immunosuppressive therapy and use corticosteroids instead as the only antirejection drug. On the other hand, some clinicians tend to resume immunosuppressive therapy as stopping immunosuppressive, beside increases the risk of transplant rejection, might increase the immune surge reaction "cytokine storm" leading to poor outcome. In COVID-19 infection, clinicians should not label immunosuppressed status in transplant recipients as a poor prognostic factor until further large-scale epidemiological investigations conducted. Also, further large studies are needed to elaborate on the management of immunosuppressive therapy during hospitalization with COVID-19 infection. Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation? COVID-19 in posttransplant patients-report of 2 cases COVID 19 in kidney transplant recipients First cases of COVID-19 in heart transplantation from Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient the COVID19 IRCCS San Matteo Pavia Task Force. SARS Cov 2 infection in a renal transplanted --patients. A case report Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression Infection in Organ Transplantation Director-General's remarks at the media briefing on 2019-nCoV on 11 The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients A Comparative Study of Clinical Presentation and Risk Factors for Adverse Outcome in Patients Hospitalised with Acute Respiratory Disease Due to MERS Coronavirus or Other Causes Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention COVID-19: consider cytokine storm syndromes and immunosuppression None of the authors have any conflicts of interests to report.-No funding received from any organizations -This paper is a literature review and does not require IRB. Consent for case report had been obtained from the patient There is no financial funding to be reported.